Compounds Produced

While we are a small group, we are actively adding compounds to our list of available tracers for use by researchers.  We have been working with investigators, not only on campus at the University of Chicago, but also with investigators at Northwestern University (both Medical and Main Campuses), University of Illinois Chicago, Illinois Institute of Technology, and Abbvie.  Some of these compounds are new and proprietary.  Often the production of these specific compounds is accompanied by pre-clinical animal studies in our iSAIRR animal imaging facility.  In other instances, the final drug product is shipped to the investigator to conduct these pre-clinical imaging studies locally.

Compounds that are readily available for use here on campus or to be shipped within the greater Chicago area some of which are: 18F-FLT or Fluorothymidine, a proliferation agent.  The University currently holds an FDA approved IND for this agent and therefore it is available for human research studies. 18F-Miso or Fluoromisonadazole, a hypoxia imaging agent. Other agents and their intended targets are listed below.   

  • 18F-FAP (or 18F- 2FA) is a nicotinic receptor agent.
  • 18F-Miso is a hypoxia marker.
  • 18F-FLT or Fluorothymidine is a proliferations agent and is available for human (research) use under an FDA approved IND held by the University
  • 18F-FDG or Fluorodeoxyglucose, an approved drug used in many human use studies.  This agent is not produced under an ANDA and therefore cannot be injected into humans and is intended for pre-clinical animal use only.
  • 18F-NaF or sodium fluoride, an approved bone seeking drug for metastases.  As for FDG above, this is not for human use.
  • K18F for phantom studies, calibrations, etc.
  • 18F-JW199 for breast and ovarian cancer.
  • 18F-JW576 for breast and ovarian cancer.
  • 18F-3F4AP.  This small molecule was developed by Pedro Brugaralos, Ph.D., then of the Department of Neurology here at the University of Chicago.  It is a demylination marked and shows promise as an imaging agent for multiple sclerosis.
  • 18F-FEPPA is a specific ligand for the translocator protein (TSPO) and is used as a positron emission tomography (PET) biomarker for glial activation and neuroinflammation.
  • 18F-GR02 is a corticosteroid that potently binds the endogenous ligand binding pocket on full length glucocorticoid receptor.
  • 18F–NaBF4 sodium/iodide symporter marker.

  • 13N-ammonia.  This like FDG above, while being an approved drug, is only available for non-human research studies at this time.
  • 18F-Nifene another nicotinic receptor agent is currently available.
  • 18F-MK6240 is a tau imaging agent that is produced under and IND and has been shipped to a variety of hospitals in the greater Chicago area that are participating in clinical trials such as the POINTER studies.
  • 18F-NAV4694 is an amyloid imaging agent that is under development and will be available under an IND for human use similar to MK6240 above.  
  • 11C-PIB an Alzheimer’s amyloid plaque imaging agent.
  • 68Ga is now able to be produced as CaCl3 and available for cold-kit labeling. 68Ga-PSMA-11 is currently under development.
  • 48VO(acac)2  Oncological imaging agent for detection and staging.
  • 15O is available as 15O-O215O-CO, 15O-CO2, and 15O-H2O.
  • 43Sc is available as PSMA-617 for prostate cancer.
  • 43Sc is available as mAb-3D1 as a MUC1 marker for breast cancer.
  • 43Sc Dotate for neuroendocrine tumors.

  • 43Sc PSMA-RGD for PSMA and alpha-v beta-3 integrin dual marker for PET imaging of prostate cancer.

Critical to using any of these agents or to developing a new compound is an understanding of the amount of work and effort that goes into even routine production of standard compounds.  Researchers new to PET imaging are often shocked at the tracer costs.  However, one has to understand that the cyclotron itself costs typically $1.7M or more and that syntheses usually involve two staff members to run the machine and do the chemistry and QC and that pre- and post-work can add another one or two hours to a synthesis that itself can easily take two hours. Precursors range from $50/run to over $250/run.  Obviously other reagents, supplies, kits, glassware, vials, needles, etc. are also needed.  Depending on the compound and the radioisotope, a single dose can cover between 1 and 4 (or more) animals such as mice or rats.  Care has to be exercised because even for mice, since the maximum injectable dose is typically 100-200 μL, the amount of drug and radioactivity needed to be produced often approaches human amounts.  Scanning costs are separate.

The fees charged are the total rate and include the costs for labor, materials and machine time. Members of the University of Chicago’s Cancer Center and non-members pay the same rate, there is no additional discount for Cancer Center members. In addition, since the University of Chicago along with Northwestern University and the University of Illinois Chicago are all members of the Chicago Biomedical Consortium, investigators all of these institutes have access to the Cyclotron Facility and they all pay the same rate for compounds.

Provided that the licenses allow for given radioisotopes, the drugs can be shipped to facilities outside of the University of Chicago.  Currently we have send drugs to: UIC, Northwestern Medical Center and Main Campus, Rush University, and Advocate Lutheran. Shipping charges depend on the location and the shipping containers are the property of the Cyclotron Facility and must be shipped back to the Facility while completely complying with Department of Transportation rules and regulations.

Shipped drugs are shipped in sterile, septum sealed vials and not syringes.